



Supplementary Materials: Cutaneous Biodistribution: A High-Resolution Methodology to Assess Bioequivalence in Topical Skin Delivery

Julie Quartier, Ninon Capony, Maria Lapteva and Yogeshvar N. Kalia

Validation of the UHPLC-MS/MS Method

Specificity in Skin Matrix

Figure S1 shows the MRM trace of (a) ECZ standard alone, (b) MCZ standard alone and (c) a mixture of both compounds.




Figure S1. Respective MRM traces of (a) ECZ standard alone (b) MCZ standard alone and (c) mixture of both compounds.

Figure S2 presents the chromatogram obtained for an ECZ standard at a concentration of 2 ng/mL, a blank skin extraction sample and a blank permeation sample. No ECZ was found in the permeation sample or in the skin sample. The method was considered as specific for ECZ quantification in skin samples.




Figure S2. MRM monitoring for ECZ in skin sample (381.1 \rightarrow 124.9 transition) chromatogram of ECZ standard (2 ng/mL), blank extraction sample and blank permeation sample.

Linearity

Calibration curves were constructed by plotting the ratio of ECZ and MCZ peak area against the ratio of ECZ and MCZ nominal concentration. A good linear fit was found in the concentration range of 1–100 ng/mL. Correlation coefficients for all calibration curves were found to be superior to 0.99.

Limit of detection and limit of quantification

The lowest concentration of ECZ detected (LOD) and lowest limit of ECZ quantified (LOQ) were found to be 0.7 ng/mL and 2.0 ng/mL, respectively.

Precision and accuracy

Intra- and inter-day precision and accuracy was assessed using 2, 5, 10, 20, 50, 100 ng/mL ECZ solutions in acetonitrile/water (80/20) skin extract. Table S1 shows a summary of intra-day accuracy and precision and Table S2 shows a summary of inter-day accuracy and precision for the method.

Table 1. Intra-day precision and accuracy for quantification of ECZ in skin sample (values are given as mean ± SD).

[ECZ]	Int	ra-Day î	1	Intra-Day 2			Intra-Day 3		
Theo	[ECZ] Meas	RSD	Recovery	[ECZ] Meas	RSD	Recovery	[ECZ] Meas	RSD	Recovery
(ng/mL)	(ng/mL)	(%)	(%)	(ng/mL)	(%)	(%)	(ng/mL)	(%)	(%)
2	2.4 ± 0.3	11.2	119.6	2.1 ± 0.0	1.2	107.1	2.1 ± 0.1	5.1	105.5
5	5.5 ± 0.2	3.6	111.0	5.5 ± 0.3	4.7	110.7	5.6 ± 0.1	2.0	111.6
10	10.8 ± 0.3	2.5	108.1	11.4 ± 0.3	2.9	114.2	10.9 ± 0.0	0.2	109.5
20	21.5 ± 0.2	2.5	107.6	21.2 ± 0.1	0.4	106.1	20.8 ± 0.3	1.6	103.9
50	53.5 ± 0.6	1.1	107.0	53.9 ± 0.8	1.5	107.9	51.5 ± 1.0	2.0	103.0
100	109.5 ± 0.4	0.4	109.5	107.3 ± 2.0	1.9	107.3	102.8 ± 1.4	1.4	102.8

Table 2. Inter-day precision and accuracy for quantification of ECZ in skin sample (values are given as mean ± SD).

[ECZ]	CZ] Intra-Day 1			Intra-Day 2			Intra-Day 3		
Theo	[ECZ] Meas	RSD	Recovery	[ECZ] Meas	RSD	Recovery	[ECZ] Meas	RSD	Recovery
(ng/mL)	(ng/mL)	(%)	(%)	(ng/mL)	(%)	(%)	(ng/mL)	(%)	(%)
2	2.1 ± 0.0	2.0	103.9	2.2 ± 0.2	10.6	112.0	2.3 ± 0.2	9.6	116.3
5	5.4 ± 0.1	2.0	104.1	5.6 ± 0.1	1.4	107.6	5.7 ± 0.1	1.0	109.9
10	10.8 ± 0.3	2.5	108.3	11.1 ± 0.4	3.4	111.0	11.2 ± 0.4	3.4	112.4
20	21.1 ± 0.7	3.3	105.6	21.2 ± 0.3	1.3	105.8	21.2 ± 0.2	0.7	106.2
50	52.6 ± 2.1	4.1	105.3	52.8 ± 0.9	1.6	105.6	53.5 ± 1.0	1.9	107.0
100	106.3 ± 4.4	4.1	106.3	107.0 ± 3.4	3.2	107.0	106.2 ± 3.1	2.9	106.2

The mean recovery observed for intra-day measurement on day 1 was from 107.0 to 119.6% (RSD 0.4–11.2%), on day 2 it was from 106.1 to 114.2% (RSD 0.4–4.7%) and on day 3 from 102.8 to 111.6% (RSD 0.2–5.1%). The mean recovery observed for inter-day 1 analysis was between 103.9 and 108.3% (RSD 2.0–4.1%), for inter-day 2 it was between 105.6 and 112.0% (RSD 1.3–10.6%), for inter-day 3 it was between 106.2 and 116.3% (RSD 0.7–9.6%).

The method was considered as accurate and precise as all measured values were within the acceptance limits of the ICH guidelines Validation of Analytical Procedure Q2(R1) (2005).

Abbreviations

Table S3 shows the abbreviations used in the article.

Table 3. Table of abbreviations.

AUC area under the curve BE bioequivalence CI confidence interval Cmax peak drug concentration in the blood ECZ econazole EMA European Medicines Agency ICH International Council for Harmonisation IVPT in vitro permeation test IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax UHPLC ultra-high pressure liquid chromotography					
CI confidence interval Cmax peak drug concentration in the blood ECZ econazole EMA European Medicines Agency ICH International Council for Harmonisation IVPT in vitro permeation test IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	AUC	area under the curve			
Cmax peak drug concentration in the blood ECZ econazole EMA European Medicines Agency ICH International Council for Harmonisation IVPT in vitro permeation test IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	BE	bioequivalence			
ECZ econazole EMA European Medicines Agency ICH International Council for Harmonisation IVPT in vitro permeation test IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	CI	confidence interval			
EMA European Medicines Agency ICH International Council for Harmonisation IVPT in vitro permeation test IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	C_{max}	peak drug concentration in the blood			
ICH International Council for Harmonisation IVPT in vitro permeation test IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	ECZ	econazole			
IVPT in vitro permeation test IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	EMA	European Medicines Agency			
IVRT in vitro release test LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	ICH	International Council for Harmonisation			
LOD limit of detection LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	IVPT	in vitro permeation test			
LOQ limit of quantification MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum T _{max} time at C _{max}	IVRT	in vitro release test			
MCZ miconazole MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	LOD	limit of detection			
MRM multiple reaction monitoring MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	LOQ	limit of quantification			
MS mass spectrometry OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum T _{max} time at C _{max}	MCZ	miconazole			
OECD Organisation for Economic Co-operation and Development RMP reference medicinal product RSD relative standard deviation SC stratum corneum T _{max} time at C _{max}	MRM	multiple reaction monitoring			
RMP reference medicinal product RSD relative standard deviation SC stratum corneum Tmax time at Cmax	MS	mass spectrometry			
RSD relative standard deviation SC stratum corneum Tmax time at Cmax	OECD	Organisation for Economic Co-operation and Development			
SC stratum corneum Tmax time at Cmax	RMP	reference medicinal product			
T _{max} time at C _{max}	RSD	relative standard deviation			
	SC	stratum corneum			
UHPLC ultra-high pressure liquid chromotography	Tmax	time at C _{max}			
	UHPLC	ultra-high pressure liquid chromotography			